Sera Prognostics reported a net loss of $9.1 million for the second quarter of 2026, widening from a loss of $8.0 million during the same period in 2025, according to the company’s financial results released on August 12, 2026. Quarterly revenue rose to $30,000 from $17,000 year-over-year, while the firm maintained $80.3 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2026.
Financial Performance and Cash Runway
Operating expenses for the quarter reached $10.0 million, up from $9.3 million in the second quarter of 2025. According to Chief Financial Officer Austin Aerts, the higher expenses reflect increased investments in evidence generation, regulatory preparation, and advocacy activities. Research and development expenses edged up to $3.5 million from $3.3 million, a total that included restructuring-related costs. Selling, general, and administrative expenses rose to $6.5 million from $6.0 million due to targeted commercial activities, marketing programs, and strategic hires.
Sera Prognostics management stated that the remaining cash reserves of $80.3 million will fund operations across key commercial milestones through 2029. The company anticipates that research and development spending will decline in future periods as resources shift toward commercialization.
Illinois Medicaid Coverage and Market Access
A central development in market access occurred in Illinois, where the state enacted legislation requiring its Medicaid program to provide coverage and reimbursement for prescribed proteomic blood tests that assess and manage the risk of spontaneous preterm birth. According to President and Chief Executive Officer Zhenya Lindgardt, the law also covers related care management services and interventions that have demonstrated improved outcomes.
Sera has initiated discussions with the Illinois Department of Healthcare and Family Services, five managed Medicaid plans, and provider organizations. The current implementation phase focuses on provider registration, network participation, contracting, credentialing, training, and workflow integration. While the state represents an eligible population of tens of thousands of Medicaid pregnancies annually, management expects utilization in Illinois to remain limited through the remainder of 2026, projecting a gradual single-digit penetration rate in subsequent years based on diagnostics industry benchmarks.
Commercial Pipeline and Payer Engagement
Sera launched its fourth commercial partnership program during the quarter, operating through a state-based initiative with a national payer under a value-added benefits framework. The company’s broader pipeline now tracks more than 20 payer opportunities across over 20 U.S. states, exceeding initial internal targets for the year.
Commercialization activities generally follow a three-stage pathway: payer engagement and evaluation, implementation preparation and contracting, and provider activation. Management notes that formal policy reviews by national payers typically require nine to 12 months, while individual state registration and subsequent contracting can take six to nine months before testing volumes begin to scale.
Clinical Evidence and European Regulatory Strategy
Clinical data supporting the PreTRM test expanded with a subgroup analysis from the PRIME study focusing on first-time mothers, who represent approximately 40% of U.S. pregnancies. The data showed a 22% reduction in neonatal intensive care unit (NICU) admissions, a twofold reduction in NICU admissions following spontaneous preterm birth, and a 30% reduction in severe composite neonatal morbidity. The study reported a number needed to screen and treat of 28 to prevent one NICU admission.
Two abstracts related to the PRIME study were accepted for the Society for Maternal-Fetal Medicine Global Congress scheduled for October, including an oral presentation and a poster presentation highlighting the economic impact of biomarker-guided interventions.
In Europe, Sera convened an expert advisory board representing nine countries and decided to perform additional performance testing on its ELISA-based assay to evaluate sample stability. Pre-application activities are slated for the third quarter of 2026, with the submission of the full CE marking package targeted for the fourth quarter.
Related reading